A carregar...
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are established effective therapies in patients with ALK-rearranged advanced non-small-cell lung cancer (NSCLC). Upon progressive disease, patients normally receive a subsequent ALK TKI. However, when disease progression occurs in a...
Na minha lista:
| Publicado no: | Case Rep Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
S. Karger AG
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7383154/ https://ncbi.nlm.nih.gov/pubmed/32774266 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000507850 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|